分子分型对1~3个腋窝淋巴结转移早期乳腺癌患者局部或区域复发风险的预测价值

doi:10.3760/cma.j.issn.1004-4221.2013.02.001

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的研究1~3个腋窝淋巴结转移早期(病理N₁期)乳腺癌分子分型与术后局部或区域复发(LR)间关系,探讨改进个体化辅助放疗指征。方法回顾分析1998—2009年本院手术的 547例病理T_1~2N₁M₀期乳腺癌根治术后未行放疗患者。根据免疫组织化学、荧光原位杂交检测结果分为Luminal A、Luminal B、HER-2过表达和三阴型,比较LR复发率(LRR)及LR生存率(LRFS),并结合临床病理特征对其LR风险进行分组分析。Kaplan-Meier法计算LRR、LRFS并Logrank法检验和单因素预后分析,多因素预后分析采用Cox模型。结果 Luminal A、Luminal B、HER-2过表达和三阴型分别占30.0%、48.6%、9.3%和12.1%。随访率97.1%,随访时间满5、10年者分别为334、127例。单因素分析显示HER-2过表达型、三阴型LR风险比Luminal A型高,5年LRR分别为19.0%、14.9%与5.3%(χ²=4.28、5.02,P=0.026、0.015),LRFS分别为73.5%、80.6%与91.1%(χ²=7.27、4.77,P=0.005、0.021)。多因素分析显示HER-2过表达型、三阴型、年龄≤35岁、pT₂期病变是LRR及LRFS的不良预后因素(χ²=2.29、2.08、18.22、6.86,P=0.020、0.016、0.001、0.005及 χ²=1.90、1.41、8.58、3.94,P=0.006、0.025、0.002、0.039)。有以上0、1和≥2个危险因素者 10年LRR分别为4.3%、14.1%和31.9%(χ²=28.03,P=0.000)。结论分子分型有助于个体化区别1~3个腋窝淋巴结转移病理N₁早期乳腺癌患者间LR风险,具有多个危险因素者应接受术后放疗。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	温戈
	张玉晶
	祝喻甲
	黄晓波
	张金山
	李凤岩
	管迅行

关键词 ：乳腺肿瘤, 分子分型, 免疫组织化学, 荧光原位杂交, 乳腺肿瘤/放射疗法, 预后

Abstract：Objective To investigate the relationship between molecular subtypes of breast cancer and postoperative loco-regional recurrence (LR) in early breast cancer patients with 1—3 positive axillary lymph nodes (pN₁) and to improve the individualized indications for post-mastectomy radiotherapy (PMRT) in these patients. Methods A total of 547 patients with pT_1－2N₁M₀ breast cancer, who received mastectomy between December 1998 and December 2009 in Sun Yat-sen University Cancer Center, were retrospectively analyzed. None of them received adjuvant radiotherapy after mastectomy. The patients were divided into luminal A group, luminal B group, HER-2-overexpressinggroup, and triple-negative group according to the molecular subtypes of breast cancer determined by immunohistochemistry and fluorescence in situ hybridization. The patients in different groups were compared in terms of LR rate (LRR) and LR-free survival (LRFS), and the risk factors for LR were analyzed in combination with clinical and pathological features. The Kaplan-Meier method was adopted to calculate LRR and LRFS;the Logrank test was usedfor survival difference analysis and univariate prognostic analysis. The Cox proportional hazards model was usedfor multivariate prognostic analysis. Results The luminal A group, luminal B group, HER-2-over expressing group, and triple-negative group accounted for 30.0%, 48.6%, 9.3%, and 12.1%, respectively, of all the patients. The follow-up rate was 97.1%;334 patients were followed up for at least 5 years, and 127 were followed up for at least 10 years. Univariate analysis showed that, compared with the luminal A group, the HER-2-overexpressing group and triple-negative group had significantly higher 5-year LRRs (19.0% vs 5.3%, χ²=4.28, P=0.026;14.9% vs 5.3%, χ²=5.02, P=0.015) and significantly lower LRFSs (73.5% vs 91.1%, χ²=7.27, P=0.005;80.6% vs 91.1%, χ²=4.77, P=0.021). Multivariate analysis revealed that HER-2 overexpression, triple-negative phenotype, age of ≤35 years, and stage pT₂ were poor prognostic factors for survival (LRR and LRFS)(χ²=2.29, 2.08, 18.22, and 6.86, P=0.020, 0.016, 0.001, and 0.005;χ²=1.90, 1.41, 8.58, and 3.94, P=0.006, 0.025, 0.002, and 0.039). The 10-year LRRs of patients with 0, 1, and ≥2 of the above risk factors were 4.3%, 14.1%, and 31.9%, respectively (χ²=28.03, P=0.000). Conclusions Molecular subtyping is helpful for individualized evaluation of LR risk in early breast cancer patients with 1—3 positive axillary lymph nodes (pN₁). PMRT should be recommended for the patients with 2 or more risk factors for LR.

Key words： Breast neoplasms, molecular subtyping Immunohistochemistry Fluorescence in situ hybridization Breast neoplasms/radiotherapy Prognosis

收稿日期: 2012-07-24

基金资助:广东省科技计划项目(2012B031800117)

通讯作者: 张玉晶 E-mail: zhangyj@sysucc.org.cn

引用本文:

温戈,张玉晶,祝喻甲等. 分子分型对1~3个腋窝淋巴结转移早期乳腺癌患者局部或区域复发风险的预测价值[J]. 中华放射肿瘤学杂志, 2013, 22(2): 89-93.

WEN Ge,ZHANG Yu-jing,ZHU Yu-jia et al. Predictive value of molecular subtyping for loco-regional recurrence in early breast cancer patients with one to three positive axillary lymph nodes[J]. Chinese Journal of Radiation Oncology, 2013, 22(2): 89-93.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2013.02.001 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2013/V22/I2/89

[1] Olivotto IA, Truong PT, Chua B. Postmastectomy radiation therapy:who needs it? J Clin Oncol,2004,22:4237-4239.
[2] 惠周光,余子豪. 我国乳腺癌改良根治术后放疗现状的调查分析.中华放射肿瘤学杂志,2005,14:471-475.
[3] Buchholz TA, Woodward WA, Duan Z, et al. Radiation use and long-term survival in breast cancer patients with T₁, T₂ primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys,2008,71:1022-1027.
[4] Park YH, Lee SJ, Cho EY, et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol,2011,22:1554-1560.
[5] 《乳腺癌HER-2 检测指南》编写组.乳腺癌HER-2 检测指南.中华病理学杂志,2006,35:631-633.
[6] Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA,2006,295:2492-2502.
[7] 王淑莲,李晔雄,宋永文,等.激素受体和人表皮生长因子受体2的表达与改良根治术后淋巴结阳性乳腺癌患者预后的关系.中华肿瘤杂志,2010,32:520-525.
[8] National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology:breast cancer (version 3.2012)[EB/OL]. Fort Washington:NCCN, 2012[2012-09-10].http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[9] Albert JM, Gonzalez-Angulo AM, Guray M, et al. Estrogen/progesterone receptor negativity and HER-2 positivity predict locoregional recurrence in patients with T_{1a, b}N₀ breast cancer. Int J Radiat Oncol Biol Phys,2010,77:1296-1302.
[10] Zhang Y, Ma QY, Dang CX, et al. Quantitative molecular diagnosis of axillary drainage fluid for prediction of locoregional failure in patients with one to three positive axillary nodes after mastectomy without adjuvant radiotherapy. Int J Radiat Oncol Biol Phys,2006,64:505-511.
[11] Harris EE, Hwang WT, Lee EA, et al. The impact of HER-2 status on local recurrence in women with stage Ⅰ－Ⅱ breast cancer treated with breast-conserving therapy. Breast J,2006,12:431-436.
[12] Wo JY, Taghian AG, Nguyen PL, et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys,2010,77:188-196.
[13] Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol,2008,26:2373-2378.
[14] Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol,2010,28:1684-1691.
[15] Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stageⅠ and Ⅱ breast cancer:Pooled results of two large European randomized trials. J Clin Oncol,2001,19:1688-1697.
[16] Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer:features of disease at presentation. Ann Oncol,2002,13:273-279.
[17] 张玉晶,孙冠青,陈娟,等.腋窝淋巴结1~3个转移的早期乳腺癌根治术后局部复发和生存的预后研究.癌症,2009,28:395-401.
[18] 王淑莲,余子豪,李晔雄,等.T₁~T₂期伴1~3个腋窝淋巴结转移乳腺癌患者改良根治术后放疗的作用.中华放射肿瘤学杂志,2009,18:291-294.
[19] 周卫兵,冯炎,陈佳艺,等.术后放疗在伴有腋窝淋巴结1~3个转移的T₁~T₂期乳腺癌中的作用.中华放射肿瘤学杂志,2006,15:396-400.
[20] Truong PT, Olivotto IA, Kader HA, et al. Selecting breast cancer patients with T₁-T₂ tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys,2005,61:1337-1347.
[21] Yang PS, Chen CM, Liu MC, et al. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T₁ to T₂ breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys,2010,77:516-522.